PhillipsK@pharmacy.ucsf.edu
(415) 502-8271 (voice)
(415) 502-0792 (fax)

Box 0613, UCSF; San Francisco, CA 94143-0613

University of Texas, Austin, BA, 1978, Psychology
Kennedy School of Government, Harvard Univ., Cambridge, MA, MPA, 1986, Policy Analysis
University of California, Berkeley, PhD, 1991, Health Services Research
Center for AIDS Prevention Studies, Univ. of CA San Francisco, Postdoc, 1993, Health Services Research

1995-1998

1998-2004

2004-present

(from 86 peer-reviewed publications)

Phillips KA, Liang SY, Ladabaum L, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. Trends in Colonoscopy for Colorectal Cancer Screening Medical Care (in press).

Phillips KA, Van Bebber SL, Issa AM. Building an evidence base for personalized medicineÕs translation to clinical practice and health policy, Personalized Medicine (in press)

Van Bebber SL, Keegan HL, Phillips KA, Issa AM. Novel personalized medicine technology: UGT1A1 testing for Irinotecan as a case study. Personalized Medicine (in press)

Issa AM, Weiss LT, Tufail W, Phillips KA, Van Bebber SL. Innovation in personalized medicine: BiDil as a case study for integrating clinical and policy developments. Personalized Medicine (in press)

Marshall D, Johnson FR, Phillips KA, Marshall JK, Thabane L, Ozdemir S, Kulin N. Measuring preferences for colorectal cancer screening using choice-format stated preferences, Value in Health (in press)

Liang SY, Haas J, Phillips KA. Measuring managed care and its environment using national surveys: a review and assessment, Medical Care Research and Review, (in press).

Haas J, Phillips KA, Fitzmaurice G, Brawarsky P, Liang SY, Klabunde CN, Brown ML. Association of regional variation in physiciansÕ colorectal cancer screening recommendations with individual use of colorectal cancer screening. (in press, Prev Chronic Dis)

Liang SY, Phillips KA, Nagamine M, Ladabaum U, Haas JS. Rates and predictors of colorectal cancer screening. Prev Chronic Dis. Available from http://www.cdc.gov/pcd/issues/2006/oct/pdf/06_0010.pdf. 2006;3(4):A117.

Phillips KA. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Affairs. 2006;25(5):1271-1280.

Keenan PS, Neumann PJ, Phillips KA. Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Affairs. 2006;25(5):1260-1269

Phillips KA, Van Bebber S, Issa A. Priming the pipeline: A review of the clinical research and policy agenda for diagnostics and biomarker development, Nature Reviews Drug Discovery 2006 Jun;5(6):463-9.

Phillips KA, Van Bebber S, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis 2006;3(3) Jul 2006 Available from: URL: http://www.cdc.gov/pcd/issues/2006/jul/05_0208.htm.

Phillips KA, Van Bebber SL. Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration. Managed Care Research and Review. 2006;63(3):301-326.

Ladabaum U, Phillips KA. Colorectal cancer screening differential costs for younger versus older americans. Am J Prev Med. 2006;30(5):378-384.

Gellad WF, Huskamp HA, Phillips KA, Haas JS. How the new Medicare drug benefit could affect vulnerable populations. Health Affairs. 2006;25(1):248-255.

Liang SY, Phillips KA, Wang H. Selection Bias into Health Plans with Specific Characteristics: A Case Study of Endogeneity of Gatekeeper Requirements and Mammography Utilization. Health Services and Outcomes Research Methodology. 2005;5(2):103-118.

Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-Effectiveness Analysis of Genetic Testing for Familial Long QT Syndrome in Symptomatic Index Cases, Heart Rhythm 2005 Dec;2(12):1294-300.

Phillips KA, Liang SY, Haas JH, Stebbins M, Alldredge B. Prescription drug dispensing limits. Managed Care Interface 2005 Jul;18(7):41-6.

Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery. 2005;4(6):500-509.

Haas JS, Phillips KA, Gerstenberger EP. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med. 2005 June;142(11): 891-897.

Phillips KA, Veenstra DL, Ramsey S, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: Issues for determining the impact to health care delivery and costs. American Journal of Managed Care 2004:10(7) :425-432.

Haas J, Phillips KA, Sonneborn D, McCulloch C, Kaplan C, Liang S. Variation in access to health care for different ethnic groups by the ethnic composition of an individual's community. Medical Care 2004:42(7):707-714.

Phillips KA, Haas JA, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J, Sonneborn D. Do gatekeeper requirements affect cancer screening utilization? Health Services Research. 2004:39(1):153-178.

Tye S, Phillips KA, Liang S. Health plan characteristics as predictors of screening mammography: Moving beyond old typologies of managed care. Health Services Research. 2004:39(1):179-206.

Phillips KA, Chen J. Willingness to use instant home HIV tests: Data from the California Behavioral Risk Factor Surveillance Survey. American Journal of Preventive Medicine, 2003:24(4): 340-348.

Phillips KA, Veenstra D, Van Bebber S, Sakowski, J. An Introduction to cost-effectiveness analysis and cost-benefit analysis of pharmacogenomics. Pharmacogenomics: May;4(3):231-9

Phillips KA, Johnson FR, Maddala T. Measuring what people value. Health Services Research, 2002: 37(6): 1659-1679.

Phillips KA, Maddala T, Johnson FR. The use of conjoint analysis to measure preferences for HIV testing. Health Services Research. 2002: 37(6): 1681-1705.

Phillips KA, Chen J. Did the U.S. Panel Report on Cost-Effectiveness in Health and Medicine influence practice?. American Journal of Preventive Medicine, 2002:22(2):98-105.

Phillips KA, Veenstra DL, Sadee W, Oren E, Lee JK. The potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review.JAMA, 2001: 286 (18): 2270-2279.

Phillips KA, Shlipak M, Coxson P, Goldman L, et al. The potential economic and health benefits of improved beta-blocker utilization following myocardial infarction. JAMA. 2000, 284(21): 2748-2754.

Phillips KA, Veenstra DL, Sadee W. Implications of the genetics revolution for health services research: Pharmacogenomics and improvements in drug therapy. HSR. 2000:35:5, Part III:128-140.

Phillips KA, Fernyak S. The costs and outcomes of HIV counseling and testing in the primary care setting: A first look, AIDS. 2000 (Sept. 29). V14(N14):2159-2169.

Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. Pharmaceutical-Sciences. 2000 (Sept. 14); 2(3): Article 29.

Phillips KA, Mayer M, Aday LA. Barriers to care among racial/ethnic groups under managed care: Data from the Medical Expenditure Panel Survey, Health Affairs. July 17, 2000.

Phillips KA, Fernyak S, Potosky A, Egorin M, Schauffler H. Do managed care plans provide more preventive services than non-managed care plans? An updated perspective, Health Affairs. 2000:19(1):102-116.

Kerlikowske K, Salzmann P, Phillips KA, Cauley J, Cummings S. Cost-effectiveness and impact on life expectancy of continuing screening mammography in women aged 70 to 79 years, JAMA. 1999;282(22):2156-63.

Phillips KA, Morrison K, Andersen R, Aday L. Understanding the context of health care utilization: Assessing environmental and provider-related variables in the behavioral model of utilization. HSR, 1998;33 (3):571-596.

Phillips KA, Kerlikowske K, Baker L, Chang S, Brown M. Factors associated with womenÕs adherence to mammography screening guidelines. HSR, 1998:33 (1):29-53.

Phillips KA, Homan R, Hiatt P, Luft H, Olson K, Kearney T, Heard S. Costs and outcomes of restricting public access to poison control centers, Medical Care, 1998:36(3):271-280.

Phillips KA, Flatt SJ, Morrison KR, Coates TJ. Potential use of home HIV testing. New England Journal of Medicine 1995;332(19):1308-1310.

Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins A, Ciccarone D. The cost-effectiveness of HIV testing of physicians and dentists. JAMA. 1994;271(11):851-858.

Phillips KA. Meta-analysis and technology assessment: a meta-analysis of the EIA HIV antibody test. The Journal of Clinical Epidemiology. 1991;44(9):925-931.

12/6/06